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Abstract MAPKAP kinase-2 and MAPKAP kinase-3 were 
both activated in response to cellular stress, interleukin-1 and 
tumour necrosis factor in KB and HeLa cells, and with identical 
kinetics. Activation of MAPKAP kinase-3, like MAPKAP 
kinase-2, was prevented by SB 203580, a specific inhibitor of 
SAPK-2, the upstream activator of MAPKAP kinase-2. 
MAPKAP kinase-3 and MAPKAP kinase-2 pbospborylated 
peptide substrates with similar kinetic constants and phospbo- 
rylated the same serine residues in HSP27 at the same relative 
rates. These results establish that MAPKAP kinase-3 lies 
'downstream' of SAPK-2 and that it is likely to have overlapping 
or identical substrates to MAPKAP kinase-2 in vivo. 
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1. Introduction 
MAP kinase-activated protein kinase-2 (MAPKAP-K2) is a 
serine/threonine-specific protein kinase that is activated by 
p42 and p44 MAP kinases in vitro, but distinct from MAP- 
KAP kinase-1 (also known as p90 rsk) [1,2]. In vivo, however, 
MAPKAP-K2 is activated by a distinct MAP kinase homo- 
logue termed stress-activated protein kinase-2 (SAPK-2), also 
known as p38 [3], p40 [4], RK [5], CSBP [6] and Mxi2 [7]. 
SAPK-2 and MAPKAP-K2 become activated within a few 
minutes when cells are stimulated with the cytokines interleu- 
kin-1 (IL-1) [4] or tumour necrosis factor (TNF) [8], with 
bacterial ipopolysaccharide (LPS) [6,9] or when stressed in 
a variety of ways, for example by exposure to heat or osmotic 
shock, UV irradiation, sodium arsenite or anisomycin [3,5,10]. 
The activation of MAPKAP-K2 by these stimuli is prevented 
if cells are first incubated with SB 203580, a specific inhibitor 
of SAPK-2 which does not affect the activity or activation of 
other MAP kinase family members, such as p42/p44 MAP 
kinases or SAPK-1 (also termed JNK) [9]. 
MAPKAP-K2 consists of a proline-rich N-terminal do- 
main, a catalytic domain which is most similar (35~,0% iden- 
tity) to the subfamily that include Ca2+/calmodulin-dependent 
protein kinases and a C-terminal tail which contains a puta- 
tive nuclear localisation signal [2]. The activation of MAP- 
KAP-K2 by SAPK-2 in vitro results from the phosphoryla- 
tion of Thr-222 and Ser-272 in the catalytic domain and Thr- 
334 in the C-terminal tail. Phosphorylation of any two of 
these three residues is sufficient for maximal activation [11]. 
These residues also become phosphorylated in vivo in an SB 
203508 sensitive manner when KB cells are stimulated with 
sodium arsenite [11]. 
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Studies on the substrate specificity of MAPKAP-K2 have 
established that it preferentially phosphorylates serine residues 
in sequences where a bulky hydrophobic residue is present at 
position n-5 and an arginine at position n-3 (where 'n' is the 
site of phosphorylation) [2]. These findings led to the discov- 
ery that heat shock protein (HSP) 27 [9,12] and the transcrip- 
tion factor CREB [13] are physiological substrates for MAP- 
KAP-K2 or a closely related homologue. MAPKAP-K2 
phosphorylates the same serine residues in HSP27 and 
CREB in vitro that become phosphorylated in response to 
cytokines and cellular stress in vivo, and the phosphorylation 
of HSP27 and CREB induced by these stimuli s prevented by 
SB 203580 at concentrations similar to those which prevent 
the activation of MAPKAP-K2. HSP27 is an actin-binding 
protein whose phosphorylation appears to stimulate the poly- 
merisation of actin. This is thought to help repair the actin 
microfilament etwork that becomes disrupted uring cellular 
stress, thereby aiding cell survival [14]. The phosphorylation 
of CREB at Serine-133 is essential to allow this transcription 
factor to transactivate genes whose promoters contain cyclic 
AMP responsive lements (CREs). The phosphorylation of 
CREB at Ser-133 may represent one of the mechanisms by 
which cellular stresses induce the transcription factor c-fos, 
since the production of c-los mRNA in response to these 
stimuli is prevented by SB 203580 [15] and the importance 
of the CRE in the c-fos promoter for the transcription of 
this gene has been well documented [16,17]. 
A protein kinase, termed MAPKAP-K3, has recently been 
identified using the yeast 'two hybrid' system to identify pro- 
teins that interact with SAPK-2 and shown to be activated by 
SAPK-2 in vitro [18]. DNA encoding the same protein kinase 
was also identified while sequencing a region of human chro- 
mosome 3 that is frequently deleted in small cell lung carci- 
nomas [19]. The amino acid sequence of MAPKAP-K3 is 75% 
identical to MAPKAP-K2 and possesses the key features of 
the latter enzyme, including the proline-rich N-terminus, the 
nuclear localisation signal at the C-terminus, and conservation 
of Thr-222, Ser-272 and Thr-334 and the amino acid se- 
quences urrounding these residues. Here we have generated 
immunoprecipitating antibodies that recognise MAPKAP-K2 
and MAPKAP-K3 specifically, and exploited them to make a 
detailed comparison of the activation of the endogenous en- 
zymes in several cell lines by cellular stresses and cytokines. 
We have also compared their substrate specificities and find 
that, in contrast o an earlier eport [19], the substrate prefer- 
ences of MAPKAP-K2 and MAPKAP-K3 are similar. 
2. Materials and methods 
2.1. Materials 
MAPKAP-K2 purified from rabbit skeletal muscle was provided by 
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Dr. N. Morrice in the MRC Protein Phosphorylation Unit and CREB 
was a generous gift from Dr. M. Comb (New England Biolabs, Bev- 
erly, MA). TNF0t was from Sigma and the sources of other materials 
are given in [5,9]. 
2.2. Expression of MAPKAP-K2 and MAPKAP-K3 in E. coli: purifi- 
cation and activation by SAPK-2 
Escherichia coli strain BL21, transformed with pGEX-5X-CL1 
DNA (encoding human MAPKAP-K3 [18]) was induced with 30 
~tM isopropyl-13-D-thiogalactoside for 20 h at 22°C. The glutathione- 
S-transferase (GST)-MAPKAP-K3 fusion protein was purified by af- 
finity chromatography on glutathione-Sepharose (Sigma) and showed 
two bands migrating on SDS/polyacrylamide g ls with apparent mo- 
lecular masses of 67 and 65 kDa. A fusion protein consisting of GST 
followed by residues 46-400 of MAPKAP-K2 was expressed in E. coli 
and purified as described [11]. This preparation also migrates as two 
bands with apparent molecular masses of 65 and 62 kDa. Each en- 
zyme was activated by incubation with the Xenopus homologue of 
SAPK-2 [11] which had been expressed in E. coli [5] and then acti- 
vated by the MAP kinase kinase homologue MKK6 from skeletal 
muscle [20]. Only the 65 kDa band of MAPKAP-K2 [11] and the 
67 kDa band of MAPKAP-K3 are phosphorylated by SAPK-2. Acti- 
vated MAPKAP-K2 and MAPKAP-K3 were mixed with equal vol- 
umes of glycerol and stored unfrozen at -20°C. 
2.3. Protein kinase assays 
MAPKAP-K2 and MAPKAP-K3 were diluted in 20 mM MOPS, 
pH 7.0, containing 1 mM EDTA, 0.01% Brij-35, 5% (v/v) glycerol, 
0.1% 2-mercaptoethanol and 0.2 mg/ml bovine serum albumin and 
then assayed [2] using the peptide KKLNRTLSVA (30 I.tM) unless 
stated otherwise. One unit of activity (U) was that amount which 
catalysed the phosphorylation f 1 nmol of KKLNRTLSVA in 1 min. 
2.4. Cell culture, stimulation and lysis 
KB [4] and HeLa [5] cells were cultured as described previously, 
incubated for 1 h with or without 10 ~tM SB 203580, then exposed to 
either chemical (0.5 mM sodium arsenite) or osmotic (0.5 M sorbitol) 
stress, or stimulated with IL-1 (20 ng/ml), TNFc~ (100 ng/ml) or ani- 
somycin (10 Izg/ml) for the times indicated in the figures. Each 6 cm 
dish of cells was lysed in 0.2 ml of buffer as described [5], except hat 
2 BM microcystin was also present in the lysis buffer. 
2.5. Chromatography of cell lysates on Mono S 
Cell lysates (0.8 mg protein) were chromatographed on Mono S as 
described [9] using a Pharmacia Smart System. 
2.6. Preparation of antibodies and immunoprecipitation 
The peptides KQAGSSSASQGCNNQG (corresponding to the C- 
terminal 15 residues of human MAPKAP-K3) and KEDKERWEDV- 
KEEMTS (corresponding to residues 343-358 of MAPKAP-K2) were 
synthesized and conjugated to bovine serum albumin and/or keyhole 
Fig. 1. Generation of antibodies that immunoprecipitate MAPKAP- 
K2 and MAPKAP-K3 specifically. (A) MAPKAP-K2 (K2) and 
MAPKAP-K3 (K3), expressed in E. coli and activated by SAPK-2 
(Section 2.2), were immunoprecipitated with anti-MAPKAP-K2 
(3 p.g) or anti-MAPKAP-K3 (10 Ixg) antibodies. The peptide kinase 
activity towards KKLNRTLSVA remaining in the supernatant (S) 
or recovered in the immunoprecipitate (P) is presented as a percen- 
tage of the activity measured in control incubations where antibod- 
ies were replaced by buffer. The results are presented as standard er- 
rors for three experiments. (B) A lysate from anisomycin-stimulated 
KB cells (0.8 mg protein) was chromatographed on Mono S (Sec- 
tion 2.5) at a flow rate of 0.2 ml/min. Fractions (0.1 ml) were as- 
sayed for peptide kinase activity using KKLNRTLSVA (O). The 
open circles (©) show the result of a separate xperiment in which 
anisomycin was omitted. The broken line (- -) shows the NaC1 
gradient and the horizontal bars the fractions pooled. (C) Pools I 
and II from B were immunoprecipitated with anti-MAPKAP-K2 (1 
txg) and anti-MAPKAP-K3 (10 [.tg) antibodies and the figure shows 
activity (measured as in A) recovered in the immunoprecipitates r - 
lative to control incubations in which the antibodies were replaced 
by buffer. The results are presented as standard errors for three ex- 
periments. 
limpet haemocyanin using glutaraldehyde and injected into sheep at 
the Scottish Antibody Production Unit (Carluke, Ayrshire). The anti- 
sera were affinity purified on peptide-agarose columns and the anti- 
bodies used to immunoprecipitate MAPKAP-K3 or MAPKAP-K2 
essentially as described in [13]. Further details are given in the figure 
legends. 
3. Results 
3.1. Generation of  antibodies that immunoprecipitate MAP-  
KAP-K2 and MAPKAP-K3  specifically 
Antibodies raised against residues 343-358 of human MAP-  
KAP-K2 immunoprecipitated MAPKAP-K2  activity specifi- 
cally but did not immunoprecipitate MAPKAP-K3  activity. 
Conversely, antibodies raised against the last 15 residues of 
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Fig. 2. Activation of MAPKAP-K2 and MAPKAP-K3 by IL-1 and cellular stresses in KB cells. Cells were stimulated for the indicated times 
with 20 ng/ml IL-1, 10 ~tg/ml anisomycin, 0.5 M sorbitol or 0.5 mM sodium arsenite. MAPKAP-K2 (©) and MAPKAP-K3 (e) were assayed 
after immunoprecipitation of these nzymes from cell lysates (50 ~tg protein) with 3 txg of anti-MAPKAP-K2 and 10 ktg of anti-MAPKAP-K3. 
The open triangles (a) show MAPKAP-K2 activity and the closed triangles (•)  MAPKAP-K3 activity in cell lysates from unstimulated cells. 
The results are shown as standard errors for four separate immunoprecipitations using two dishes of cells. 
MAPKAP-K3 immunoprecipitated MAPKAP-K3 activity 
specifically, but did not immunoprecipitate MAPKAP-K2 ac- 
tivity (Fig. 1A). 
In order to further establish the specificity of each antibody 
and to identify MAPKAP-K3, lysates from anisomycin-stimu- 
lated KB cells were chromatographed on Mono S and the 
fractions assayed for protein kinase activity towards 
KKLNRTLSVA, the standard substrate for MAPKAP-K2 
(Fig. 1B). These experiments demonstrated that the major 
peak of activity corresponded to MAPKAP-K2 and the minor 
peak, eluting at a higher salt concentration, to MAPKAP-K3 
(Fig. 1C). 
3.2. Activation of  MAPKAP-K3 and MAPKAP-K2 by cellular 
stress and cytokines 
MAPKAP-K3 and MAPKAP-K2 were immunoprecipi- 
tated from the lysates of KB cells and HeLa cells previously 
stimulated with cytokines or exposed to cellular stress. These 
experiments demonstrated that MAPKAP-K3 was activated 
by several stimuli known to activate MAPKAP-K2 with simi- 
lar kinetics in each case (Figs. 2 and 3). Consistent with the 
results presented in Fig. 1B, MAPKAP-K3 accounted for 15- 
20% and MAPKAP-K2 for 80-85% of the activity immuno- 
precipitated from the lysates with every stimulus, except for 
arsenite which induced a higher level of activation of MAP- 
KAP-K3 (Figs. 2 and 3). The activation of MAPKAP-K3, 
like MAPKAP-K2, was largely prevented by SB 203580 in 
both KB cells (Fig. 4) and HeLa cells (data not shown). 
3.3. Comparison of the substrate specificity of MAPKAP-K3 
with that of MAPKAP-K2 
In the present study, we activated MAPKAP-K3 and MAP- 
KAP-K2 with SAPK-2 and compared their specificities to- 
wards a panel of synthetic peptides previously used to study 
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Fig. 3. Activation of MAPKAP-K2 and MAPKAP-K3 by TNF and 
cellular stress in HeLa ceils. Cells were stimulated for the indicated 
times with 100 ng/ml TNF or 0.5 mM sodium arsenite. MAPKAP- 
K2 (O) and MAPKAP-K3 (~) were assayed after immunoprecipita- 
tion of these enzymes from cell lysates as in Fig. 2. The open trian- 
gles (zx) show MAPKAP-K2 activity and the closed triangles (A) 
MAPKAP-K3 activity in cell lysates from unstimulated cells. The 
results are shown as standard errors for four separate immunopreci- 
pitations using two dishes of cells. 
MAPKAP-K2 [2]. These experiments established that, like 
MAPKAP-K2,  MAPKAP-K3 requires a bulky hydrophobic 
residue at position n-5 to phosphorylate peptides with a low 
Km value (Leu=Phe > Val>>Ala) and that MAPKAP-K3,  
like MAPKAP-K2,  cannot tolerate replacement of Arg by 
Lys at n-3, or Val by either Pro or Lys at position n+ 1 (Table 
1). However, MAPKAP-K3 was able to tolerate replacement 
of Ser by Thr at position 'n' to a somewhat greater extent 
than MAPKAP-K2 (Table 1). MAPKAP-K2 expressed in E. 
coli and then activated with SAPK-2 phosphorylated each 
peptide with similar kinetic constants to MAPKAP-K2 iso- 
lated from rabbit skeletal muscle (data not shown). 
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Fig. 4. SB 203580 prevents the activation of MAPKAP-K2 and 
MAPKAP-K3 by cellular stress and IL-1 in KB cells. Cells were in- 
cubated for 1 h in the absence or presence of 10 IxM SB 203580 
and then for 15 min with 20 ng/ml IL-1, 10 [.tg/ml anisomycin 
(ANS), 0.5 M sorbitol (osmotic shock-OSM) or 0.5 mM sodium ar- 
senite (ARS) in the continued presence of SB 203580. MAPKAP- 
K2 and MAPKAP-K3 were assayed after immunoprecipitation from 
the cell lysates as in Fig. 2. The results are shown as standard er- 
rors for four separate immunoprecipitations using two dishes of 
cells. 
Activated MAPKAP-K3 phosphorylated HSP27 at a simi- 
lar rate to activated MAPKAP-K2 when activities were 
matched towards the standard peptide KKLNRTLSVA.  The 
three serine residues in HSP27 phosphorylated by MAPKAP-  
K2 [12] were also phosphorylated at the same relative rates by 
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Fig. 5. Phosphorylation of HSP27 by MAPKAP-K2 and MAP- 
KAP-K3. HSP 27 (2 ~M) was incubated at 30°C in 0.08 ml of 50 
mM sodium 13-glycerophosphate pH 7.4, 0.1 mM EGTA, 0.1% (v/v) 
2-mercaptoethanol, 10 mM magnesium acetate/0.1 mM [Ta2P]ATP 
(6×106 cpm/nmol), with or without 10 U/ml MAPKAP-K2 or 
MAPKAP-K3. After incubation for the indicated times, an aliquot 
(15 ~1) was removed and the incorporation of phosphate into 
HSP27 protein (O) measured after precipitation with trichloroacetic 
acid [12]. The precipitated HSP27 was digested with trypsin, chro- 
matographed on a Vydac C18 column to resolve the different phos- 
phopeptides as described [12] and the incorporation of phosphate 
into the peptides containing Ser-82 (O), Ser-78 (zx) and Serl5 (A) 
was quantitated. 
MAPKAP-K3 (Ser-82>>Ser-78 >Ser-15; Fig. 5). The two 
protein kinases also phosphorylated CREB at similar rates 
(data not shown). 
4. Discussion 
In this paper we present he first comparison of the activa- 
tion of MAPKAP-K2 and MAPKAP-K3 in vivo and the 
substrate specificities of these enzymes in vitro. These studies 
demonstrate that MAPKAP-K2 and MAPKAP-K3 are acti- 
vated by the same stimuli and with identical kinetics (Figs. 2 
and 3), and establish that MAPKAP-3, like MAPKAP-K2, is 
a stress and cytokine-activated protein kinase which lies 
'downstream' of SAPK-2 (Fig. 4). The activation of an epi- 
tope-tagged version of MAPKAP-K3 by TNF or osmotic 
shock and blockade of its activation by SB 203580 has been 
demonstrated previously after its transfection i to HeLa cells 
[18]. However, by raising antibodies that immunoprecipitate 
either MAPKAP-K2 or MAPKAP-K3, we have been able to 
study the activation of the endogenous enzymes in the same 
cell lysates. This has avoided expression/overexpression of epi- 
tope-tagged proteins which has the potential to produce mis- 
leading results. For example, the overexpression f MEK ki- 
nase triggers the activation of the growth factor-stimulated 
MAP kinase cascade as well as the stress-activated pathway 
leading to the activation of SAPK-1, although at lower levels 
of expression MEK kinase is reported to activate the latter 
pathway relatively specifically [21,22]. Moreover, MAPKAP- 
K2 transfected into COS cells can be activated by the growth 
factor stimulated MAP kinase pathway, in contrast o the 
endogenous MAPKAP-K2 which is only activated by 
SAPK-2 (R. BenLevy and C.J. Marshall, pers. Commun., 
1996). 
In KB and HeLa cells, MAPKAP-K3 only accounted for 
15-20% of the SB 203580 sensitive MAPKAP kinase activity 
observed after stimulation with IL-1, TNF, anisomycin or 
osmotic shock and for 30-40% of the activity observed after 
exposure to sodium arsenite (Figs. 2 and 3). It is not yet clear 
whether this difference reflects the relative levels of these ki- 
nases in vivo or whether MAPKAP-K2 is activated preferen- 
tially by SAPK-2. The greater activation of MAPKAP-K3 
after stimulation with sodium arsenite (Figs. 2 and 3) suggests 
that the latter explanation is correct. In other cells, MAP- 
KAP-K3 made an even lower contribution accounting for 
only 11% of the total MAPKAP-K2+MAPKAP-K3 activity 
in arsenite-stimulated human A431 fibroblasts, 6% in arsenite- 
stimulated mouse Swiss-3T3 cells and a negligible proportion 
in arsenite-stimulated (or LPS-stimulated [9]) human THP1 
monocytes and rat PC12 cells (A. Clifton, unpublished experi- 
ments). The last mentioned observation is consistent with the 
very low levels of MAPKAP-K3 mRNA found in the brain 
[19]. 
Our results demonstrate that the substrate specificity of 
MAPKAP-K3 is similar to that of MAPKAP-K2. In a side 
by side comparison, we found that both kinases phosphoryl- 
ated a panel of synthetic peptides with similar kinetics (Table 
1), and phosphorylated HSP27 and CREB at similar rates. 
Moreover, the three serine residues in HSP27 were also phos- 
phorylated at the same relative rates (Fig. 5). This demon- 
strates that MAPKAP-K3, like MAPKAP-K2, preferentially 
phosphorylates the sequence Hyd-Xaa-Arg-Xaa-Xaa-Ser-Xaa, 
where Hyd is a bulky hydrophobic residue. However, MAP- 
KAP-K3 can tolerate replacement of serine by threonine at 
the site of phosphorylation better than can MAPKAP-K2. In 
contrast, Sithanandam et al. [19], using the same panel of 
synthetic peptides, reported that MAPKAP-K3 had a novel 
specificity different from MAPKAP-K2. The reason for this 
discrepancy with our work is unclear, although it should be 
noted that no side by side comparison with MAPKAP-K2 
was made in their study. In summary, the finding that MAP- 
KAP-K2 and MAPKAP-K3 are activated by the same signal 
transduction pathway in vivo and that they have similar spe- 
cificities in vitro, suggests that they are also likely to have 
overlapping or identical substrate specificities in vivo. 
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Table 1 
Comparison of the specificities of MAPKAP-K2 and MAPKAP-K3 towards ynthetic peptides 
Peptide MAPKAP-K2 MAPKAP-K3 
Km (~tM) Vm~ gm (].tM) Vm~ 
KKLNRTLSVA 3.8 + 0.9 100 2.5+ 0.2 100 
KK~NRTLSVA 5.9+ 1.7 113+ 19 2.8+ 0.1 104+3 
KKWvq',IRTLSVA 18 + 3 102+24 7.2+ 0.6 90+2 
KK~NRTLSVA 274 +54 91 _ 12 86 + 14 81 _+5 
KKLNRTLTVA 170 _+17 31_+ 1 53 + 1 65-+1 
Peptide Activity at 30 laM relative to KKLNRTLSVA 
MAPKAP-K2 MAPKAP-K3 
KKLNRTLSVA 100 100 
KKKNRTLSVA 6 11 
KKENRTLSVA 5 8 
KK~NKTLSVA 3 6 
KKLNRTLTVA 6 25 
KKLNRTLS'PA 4 6 
KKLNRTLSKA < 1 < 1 
The data are presented as standard eviations for three separate experiments with each peptide xcept KKLNRTLTVA which shows the average of 
two independent experiments. Vnm x is the maximal activity at saturating substrate concentration relative to KKLNRTLSVA. 
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